data_L89
#
_chem_comp.id                                        L89
_chem_comp.name                                      pyridine-3,4-diamine
_chem_comp.type                                      NON-POLYMER
_chem_comp.pdbx_type                                 HETAIN
_chem_comp.formula                                   "C5 H7 N3"
_chem_comp.mon_nstd_parent_comp_id                   ?
_chem_comp.pdbx_synonyms                             ?
_chem_comp.pdbx_formal_charge                        0
_chem_comp.pdbx_initial_date                         2017-04-13
_chem_comp.pdbx_modified_date                        2017-07-07
_chem_comp.pdbx_ambiguous_flag                       N
_chem_comp.pdbx_release_status                       REL
_chem_comp.pdbx_replaced_by                          ?
_chem_comp.pdbx_replaces                             ?
_chem_comp.formula_weight                            109.129
_chem_comp.one_letter_code                           ?
_chem_comp.three_letter_code                         L89
_chem_comp.pdbx_model_coordinates_details            ?
_chem_comp.pdbx_model_coordinates_missing_flag       N
_chem_comp.pdbx_ideal_coordinates_details            Corina
_chem_comp.pdbx_ideal_coordinates_missing_flag       N
_chem_comp.pdbx_model_coordinates_db_code            5NOW
_chem_comp.pdbx_subcomponent_list                    ?
_chem_comp.pdbx_processing_site                      EBI

#
loop_
_chem_comp_atom.comp_id                        
_chem_comp_atom.atom_id                        
_chem_comp_atom.alt_atom_id                    
_chem_comp_atom.type_symbol                    
_chem_comp_atom.charge                         
_chem_comp_atom.pdbx_align                     
_chem_comp_atom.pdbx_aromatic_flag             
_chem_comp_atom.pdbx_leaving_atom_flag         
_chem_comp_atom.pdbx_stereo_config             
_chem_comp_atom.model_Cartn_x                  
_chem_comp_atom.model_Cartn_y                  
_chem_comp_atom.model_Cartn_z                  
_chem_comp_atom.pdbx_model_Cartn_x_ideal       
_chem_comp_atom.pdbx_model_Cartn_y_ideal       
_chem_comp_atom.pdbx_model_Cartn_z_ideal       
_chem_comp_atom.pdbx_component_atom_id         
_chem_comp_atom.pdbx_component_comp_id         
_chem_comp_atom.pdbx_ordinal                   
L89 N2 N1 N 0 1 N N N -6.874 19.317 -8.796  1.709  1.418 -0.001 N2 L89  1
L89 C4 C1 C 0 1 Y N N -5.669 19.747 -8.350  0.511  0.693 -0.002 C4 L89  2
L89  C C2 C 0 1 Y N N -5.357 21.095 -8.370  0.527 -0.707 -0.000  C L89  3
L89  N N2 N 0 1 N N N -6.247 22.005 -8.834  1.732 -1.410  0.002  N L89  4
L89 C3 C3 C 0 1 Y N N -4.734 18.838 -7.868 -0.708  1.349  0.002 C3 L89  5
L89 N1 N3 N 0 1 Y N N -3.538 19.234 -7.422 -1.840  0.670  0.002 N1 L89  6
L89 C2 C4 C 0 1 Y N N -3.223 20.533 -7.435 -1.863 -0.649 -0.002 C2 L89  7
L89 C1 C5 C 0 1 Y N N -4.110 21.495 -7.904 -0.692 -1.380 -0.001 C1 L89  8
L89 H1 H1 H 0 1 N N N -6.927 18.322 -8.709  1.689  2.387  0.002 H1 L89  9
L89 H2 H2 H 0 1 N N N -7.600 19.738 -8.253  2.559  0.950  0.000 H2 L89 10
L89 H3 H3 H 0 1 N N N -5.851 22.921 -8.772  2.574 -0.928  0.002 H3 L89 11
L89 H4 H4 H 0 1 N N N -6.466 21.800 -9.788  1.728 -2.380  0.003 H4 L89 12
L89 H5 H5 H 0 1 N N N -4.980 17.787 -7.854 -0.733  2.429  0.005 H5 L89 13
L89 H6 H6 H 0 1 N N N -2.254 20.843 -7.072 -2.812 -1.164 -0.002 H6 L89 14
L89 H7 H7 H 0 1 N N N -3.834 22.539 -7.906 -0.721 -2.459  0.000 H7 L89 15
#
loop_
_chem_comp_bond.comp_id                  
_chem_comp_bond.atom_id_1                
_chem_comp_bond.atom_id_2                
_chem_comp_bond.value_order              
_chem_comp_bond.pdbx_aromatic_flag       
_chem_comp_bond.pdbx_stereo_config       
_chem_comp_bond.pdbx_ordinal             
L89  N  C SING N N  1
L89 N2 C4 SING N N  2
L89  C C4 DOUB Y N  3
L89  C C1 SING Y N  4
L89 C4 C3 SING Y N  5
L89 C1 C2 DOUB Y N  6
L89 C3 N1 DOUB Y N  7
L89 C2 N1 SING Y N  8
L89 N2 H1 SING N N  9
L89 N2 H2 SING N N 10
L89  N H3 SING N N 11
L89  N H4 SING N N 12
L89 C3 H5 SING N N 13
L89 C2 H6 SING N N 14
L89 C1 H7 SING N N 15
#
loop_
_pdbx_chem_comp_descriptor.comp_id               
_pdbx_chem_comp_descriptor.type                  
_pdbx_chem_comp_descriptor.program               
_pdbx_chem_comp_descriptor.program_version       
_pdbx_chem_comp_descriptor.descriptor            
L89            InChI                InChI  1.03 InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)
L89         InChIKey                InChI  1.03                           OYTKINVCDFNREN-UHFFFAOYSA-N
L89 SMILES_CANONICAL               CACTVS 3.385                                            Nc1ccncc1N
L89           SMILES               CACTVS 3.385                                            Nc1ccncc1N
L89 SMILES_CANONICAL "OpenEye OEToolkits" 2.0.6                                          c1cncc(c1N)N
L89           SMILES "OpenEye OEToolkits" 2.0.6                                          c1cncc(c1N)N
#
_pdbx_chem_comp_identifier.comp_id               L89
_pdbx_chem_comp_identifier.type                  "SYSTEMATIC NAME"
_pdbx_chem_comp_identifier.program               "OpenEye OEToolkits"
_pdbx_chem_comp_identifier.program_version       2.0.6
_pdbx_chem_comp_identifier.identifier            pyridine-3,4-diamine

#
loop_
_pdbx_chem_comp_audit.comp_id               
_pdbx_chem_comp_audit.action_type           
_pdbx_chem_comp_audit.date                  
_pdbx_chem_comp_audit.processing_site       
L89 "Create component" 2017-04-13  EBI
L89  "Initial release" 2017-07-12 RCSB
#
_pdbe_chem_comp_drugbank_details.comp_id                   L89
_pdbe_chem_comp_drugbank_details.drugbank_id               DB11640
_pdbe_chem_comp_drugbank_details.type                      "small molecule"
_pdbe_chem_comp_drugbank_details.name                      Amifampridine
_pdbe_chem_comp_drugbank_details.description               "Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations [A33863]. It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambertâ€“Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s [L3171]. Amifampridine phosphate is a more stable salt that serves as an active ingredient of EMA-approved Firdapse, which was previously marketed as Zenas. It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819].  LEMS is a rare auto-immune disorder of the neuromuscular junction that is characterized by proximal muscle weakness, depressed tendon reflexes, and posttetanic potentiation in addition to autonomic dysfunction [A33863]. About 50-60% of the patients develop more rapidly progressive LEMS and small cell lung cancer, which influences the prognosis [A33863]. Patients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which is mainly responsible for causing symptoms of LEMS [A33863]. Reduced acetylcholine release at the neuromuscular junction leads to decreased frequency of miniature endplate potentials of normal amplitude, and insufficient acetylcholine levels for the activation of postsynaptic muscle fibers following a single nerve impulse [A33863]. This leads to the reduction of the compound muscle action potential (CMAP) [A33863]. Treatment for LEMS include immunotherapy such as conventional immunosuppression or intravenous immunoglobulins, however such treatments are recommended in patients in whom symptomatic treatment would not suffice [A33863]. Amifampridine is the nonimmune treatment options for LEMS.   In phase III clinical trials of adult patients with LEMS, treatment of amifampridine significantly improved symptoms of LEMS compared to placebo with good tolerance [A33864]. It was demonstrated in clinical studies involving healthy volunteers that the pharmacokinetics and systemic exposure to amifampridine is affected by the genetic differences in N-acetyl-transferase (NAT) enzymes (acetylator phenotype) and NAT2 genotype, which is subject to genetic variation [F272]. Slow acetylators were at higher risk for experiencing drug-associated adverse reactions, such as paresthesias, nausea, and headache [F272]."
_pdbe_chem_comp_drugbank_details.cas_number                54-96-6
_pdbe_chem_comp_drugbank_details.mechanism_of_action       "Amifampridine is a symptomatic treatment that increases acetylcholine concentrations at the neuromuscular junction. It selectively blocks presynaptic fast voltage-gated potassium channels, thereby prolonging cell membrane depolarization and action potential, and augmenting calcium transport into the nerve endings. Increased intracellular calcium enhances the exocytosis of acetylcholine-containing vesicles and enhances impulse transmission at central, autonomic, and neuromuscular synapses [A33863, F272]. Amifampridine improves muscle strength and resting compound muscle action potential (CMAP) amplitudes with an overall weighted mean difference of 1.69 mV [F272]."

#
_pdbe_chem_comp_drugbank_classification.comp_id           L89
_pdbe_chem_comp_drugbank_classification.drugbank_id       DB11640
_pdbe_chem_comp_drugbank_classification.parent            "Aminopyridines and derivatives"
_pdbe_chem_comp_drugbank_classification.kingdom           "Organic compounds"
_pdbe_chem_comp_drugbank_classification.class             "Pyridines and derivatives"
_pdbe_chem_comp_drugbank_classification.superclass        "Organoheterocyclic compounds"
_pdbe_chem_comp_drugbank_classification.description       "This compound belongs to the class of organic compounds known as aminopyridines and derivatives. These are organic heterocyclic compounds containing an amino group attached to a pyridine ring."

#
_pdbe_chem_comp_drugbank_targets.comp_id                        L89
_pdbe_chem_comp_drugbank_targets.drugbank_id                    DB11640
_pdbe_chem_comp_drugbank_targets.name                           "Potassium voltage-gated channel subfamily A member 1"
_pdbe_chem_comp_drugbank_targets.organism                       Humans
_pdbe_chem_comp_drugbank_targets.uniprot_id                     Q09470
_pdbe_chem_comp_drugbank_targets.pharmacologically_active       yes
_pdbe_chem_comp_drugbank_targets.ordinal                        1

#
loop_
_pdbx_chem_comp_synonyms.comp_id          
_pdbx_chem_comp_synonyms.name             
_pdbx_chem_comp_synonyms.provenance       
L89    Pyridine-3,4-Diamine   ChEMBL
L89                     DAP   ChEMBL
L89           Amifampridine   ChEMBL
L89 3,4-Diammoniopyridinium   ChEMBL
L89                   4-DAP   ChEMBL
L89                 3,4-DAP DrugBank
L89     3,4-Diaminopyridine DrugBank
L89     3,4-Pyridinediamine DrugBank
L89     4,5-Diaminopyridine DrugBank
L89                     DAP DrugBank
#
loop_
_software.name              
_software.version           
_software.description       
       rdkit 2019.03.2                                      "Core functionality."
pdbeccdutils     0.5.2 "Wrapper to provide 2D templates and molecular fragments."
#
loop_
_pdbe_chem_comp_atom_depiction.comp_id             
_pdbe_chem_comp_atom_depiction.atom_id             
_pdbe_chem_comp_atom_depiction.element             
_pdbe_chem_comp_atom_depiction.model_Cartn_x       
_pdbe_chem_comp_atom_depiction.model_Cartn_y       
_pdbe_chem_comp_atom_depiction.pdbx_ordinal        
L89 N2 N 3.805  0.517 1
L89 C4 C 5.104 -0.233 2
L89  C C 6.404  0.517 3
L89  N N 6.404  2.018 4
L89 C3 C 5.104 -1.732 5
L89 N1 N 6.404 -2.482 6
L89 C2 C 7.702 -1.732 7
L89 C1 C 7.702 -0.233 8
#
loop_
_pdbe_chem_comp_bond_depiction.comp_id            
_pdbe_chem_comp_bond_depiction.atom_id_1          
_pdbe_chem_comp_bond_depiction.atom_id_2          
_pdbe_chem_comp_bond_depiction.value_order        
_pdbe_chem_comp_bond_depiction.bond_dir           
_pdbe_chem_comp_bond_depiction.pdbx_ordinal       
L89  N  C SINGLE NONE 1
L89 N2 C4 SINGLE NONE 2
L89  C C4 DOUBLE NONE 3
L89  C C1 SINGLE NONE 4
L89 C4 C3 SINGLE NONE 5
L89 C1 C2 DOUBLE NONE 6
L89 C3 N1 DOUBLE NONE 7
L89 C2 N1 SINGLE NONE 8
#
loop_
_pdbe_chem_comp_substructure.comp_id                      
_pdbe_chem_comp_substructure.substructure_name            
_pdbe_chem_comp_substructure.id                           
_pdbe_chem_comp_substructure.substructure_type            
_pdbe_chem_comp_substructure.substructure_smiles          
_pdbe_chem_comp_substructure.substructure_inchis          
_pdbe_chem_comp_substructure.substructure_inchikeys       
L89 MurckoScaffold S1 scaffold c1ccncc1 InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H JUJWROOIHBZHMG-UHFFFAOYSA-N
L89       pyridine F1 fragment c1ccncc1 InChI=1S/C5H5N/c1-2-4-6-5-3-1/h1-5H JUJWROOIHBZHMG-UHFFFAOYSA-N
#
loop_
_pdbe_chem_comp_substructure_mapping.comp_id                    
_pdbe_chem_comp_substructure_mapping.atom_id                    
_pdbe_chem_comp_substructure_mapping.substructure_id            
_pdbe_chem_comp_substructure_mapping.substructure_ordinal       
L89 C3 F1 1
L89 C4 F1 1
L89  C F1 1
L89 C1 F1 1
L89 C2 F1 1
L89 N1 F1 1
L89 C4 S1 1
L89  C S1 1
L89 C3 S1 1
L89 N1 S1 1
L89 C2 S1 1
L89 C1 S1 1
#
_pdbe_chem_comp_rdkit_properties.comp_id                               L89
_pdbe_chem_comp_rdkit_properties.exactmw                               109.064
_pdbe_chem_comp_rdkit_properties.lipinskiHBA                           3
_pdbe_chem_comp_rdkit_properties.lipinskiHBD                           4
_pdbe_chem_comp_rdkit_properties.NumRotatableBonds                     2
_pdbe_chem_comp_rdkit_properties.NumHBD                                2
_pdbe_chem_comp_rdkit_properties.NumHBA                                3
_pdbe_chem_comp_rdkit_properties.NumHeteroatoms                        3
_pdbe_chem_comp_rdkit_properties.NumAmideBonds                         0
_pdbe_chem_comp_rdkit_properties.FractionCSP3                          0
_pdbe_chem_comp_rdkit_properties.NumRings                              1
_pdbe_chem_comp_rdkit_properties.NumAromaticRings                      1
_pdbe_chem_comp_rdkit_properties.NumAliphaticRings                     0
_pdbe_chem_comp_rdkit_properties.NumSaturatedRings                     0
_pdbe_chem_comp_rdkit_properties.NumHeterocycles                       1
_pdbe_chem_comp_rdkit_properties.NumAromaticHeterocycles               1
_pdbe_chem_comp_rdkit_properties.NumSaturatedHeterocycles              0
_pdbe_chem_comp_rdkit_properties.NumAliphaticHeterocycles              0
_pdbe_chem_comp_rdkit_properties.NumSpiroAtoms                         0
_pdbe_chem_comp_rdkit_properties.NumBridgeheadAtoms                    0
_pdbe_chem_comp_rdkit_properties.NumAtomStereoCenters                  0
_pdbe_chem_comp_rdkit_properties.NumUnspecifiedAtomStereoCenters       0
_pdbe_chem_comp_rdkit_properties.labuteASA                             57.398
_pdbe_chem_comp_rdkit_properties.tpsa                                  64.930
_pdbe_chem_comp_rdkit_properties.CrippenClogP                          -0.515
_pdbe_chem_comp_rdkit_properties.CrippenMR                             31.414
_pdbe_chem_comp_rdkit_properties.NumHeavyAtoms                         8

#
loop_
_pdbe_chem_comp_external_mappings.comp_id           
_pdbe_chem_comp_external_mappings.source            
_pdbe_chem_comp_external_mappings.resource          
_pdbe_chem_comp_external_mappings.resource_id       
L89 UniChem     ChEMBL     CHEMBL354077
L89 UniChem   DrugBank          DB11640
L89 UniChem      ChEBI           135948
L89 UniChem       ZINC ZINC000000164000
L89 UniChem NMRShiftDB         10017792
L89 UniChem  BindingDb         50416493
#
loop_
_pdbe_chem_comp_rdkit_conformer.comp_id             
_pdbe_chem_comp_rdkit_conformer.atom_id             
_pdbe_chem_comp_rdkit_conformer.Cartn_x_rdkit       
_pdbe_chem_comp_rdkit_conformer.Cartn_y_rdkit       
_pdbe_chem_comp_rdkit_conformer.Cartn_z_rdkit       
_pdbe_chem_comp_rdkit_conformer.rdkit_method        
_pdbe_chem_comp_rdkit_conformer.rdkit_ordinal       
L89 N2  1.343  1.634 -0.377 ETKDGv2  1
L89 C4  0.225  0.775 -0.116 ETKDGv2  2
L89  C  0.351 -0.566  0.033 ETKDGv2  3
L89  N  1.624 -1.227  0.024 ETKDGv2  4
L89 C3 -1.127  1.377 -0.031 ETKDGv2  5
L89 N1 -2.173  0.629  0.161 ETKDGv2  6
L89 C2 -2.065 -0.795  0.300 ETKDGv2  7
L89 C1 -0.867 -1.385  0.240 ETKDGv2  8
L89 H1  2.280  1.276 -0.660 ETKDGv2  9
L89 H2  1.210  2.669 -0.393 ETKDGv2 10
L89 H3  2.529 -0.717  0.098 ETKDGv2 11
L89 H4  1.667 -2.270  0.048 ETKDGv2 12
L89 H5 -1.252  2.447 -0.135 ETKDGv2 13
L89 H6 -2.956 -1.389  0.455 ETKDGv2 14
L89 H7 -0.790 -2.459  0.351 ETKDGv2 15
#
